A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation
PurposeTheranostics integrates diagnostic imaging (e.g., 18F-PSMA-1007 PET) with targeted radioligand therapy (TRT; e.g., 177Lu-PSMA-617), but personalized dosimetry remains challenging due to complex dose calculations. Current methods like Monte Carlo simulations are accurate but require impractica...
Saved in:
| Main Authors: | Thanh Tai Duong, Danny De Sarno, Hatim Fakir, Glenn Bauman, Martin Martinov, Rowan M. Thomson, Ting-Yim Lee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1600821/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01) -
Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01) -
Toward the standardization of radiopharmaceutical therapies: a technical note evaluating a clinical dosimetry workflow for single-time-point 177Lu SPECT/CT-based therapies
by: Taehyung Peter Kim, et al.
Published: (2025-08-01) -
Personalized three-dimensional dose calculation method based on multi-modal images in dosimetry assessment of prostate cancer with skull metastasis: a Monte Carlo simulation study
by: Feng Tian, et al.
Published: (2025-07-01) -
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01)